1
|
Beaudier P, Vilotte F, Simon M, Muggiolu G, Le Trequesser Q, Devès G, Plawinski L, Mikael A, Caron J, Kantor G, Dupuy D, Delville MH, Barberet P, Seznec H. Sarcoma cell-specific radiation sensitization by titanate scrolled nanosheets: insights from physicochemical analysis and transcriptomic profiling. Sci Rep 2024; 14:3295. [PMID: 38332121 PMCID: PMC10853196 DOI: 10.1038/s41598-024-53847-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 02/06/2024] [Indexed: 02/10/2024] Open
Abstract
This study aimed to explore the potential of metal oxides such as Titanate Scrolled Nanosheets (TNs) in improving the radiosensitivity of sarcoma cell lines. Enhancing the response of cancer cells to radiation therapy is crucial, and one promising approach involves utilizing metal oxide nanoparticles. We focused on the impact of exposing two human sarcoma cell lines to both TNs and ionizing radiation (IR). Our research was prompted by previous in vitro toxicity assessments, revealing a correlation between TNs' toxicity and alterations in intracellular calcium homeostasis. A hydrothermal process using titanium dioxide powder in an alkaline solution produced the TNs. Our study quantified the intracellular content of TNs and analyzed their impact on radiation-induced responses. This assessment encompassed PIXE analysis, cell proliferation, and transcriptomic analysis. We observed that sarcoma cells internalized TNs, causing alterations in intracellular calcium homeostasis. We also found that irradiation influence intracellular calcium levels. Transcriptomic analysis revealed marked disparities in the gene expression patterns between the two sarcoma cell lines, suggesting a potential cell-line-dependent nano-sensitization to IR. These results significantly advance our comprehension of the interplay between TNs, IR, and cancer cells, promising potential enhancement of radiation therapy efficiency.
Collapse
Affiliation(s)
- Pierre Beaudier
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
- U1212, IECB, INSERM, University of Bordeaux, 33607, Pessac, France
| | - Florent Vilotte
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
- Radiation Oncology Unit, Institut Bergonié, 33076, Bordeaux, France
| | - Marina Simon
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
| | - Giovanna Muggiolu
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
| | | | - Guillaume Devès
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
| | - Laurent Plawinski
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
| | - Antoine Mikael
- Radiation Oncology Unit, Institut Bergonié, 33076, Bordeaux, France
| | - Jérôme Caron
- Radiation Oncology Unit, Institut Bergonié, 33076, Bordeaux, France
| | - Guy Kantor
- Radiation Oncology Unit, Institut Bergonié, 33076, Bordeaux, France
| | - Denis Dupuy
- U1212, IECB, INSERM, University of Bordeaux, 33607, Pessac, France
| | | | - Philippe Barberet
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France
| | - Hervé Seznec
- UMR 5797, LP2I Bordeaux, CNRS, University of Bordeaux, 33170, Gradignan, France.
| |
Collapse
|
2
|
Bugdadi A, Cherif MA, Loganadane G, Brugières P, Marniche A, Itti E, Belkacemi Y, Tauziède-Espariat A, Palfi S, Senova S. Epithelioid glioblastoma diagnosed 70 years after craniofacial radiotherapy. Acta Neurochir (Wien) 2023; 165:2769-2774. [PMID: 37269332 DOI: 10.1007/s00701-023-05637-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2023] [Accepted: 05/14/2023] [Indexed: 06/05/2023]
Abstract
The authors report a rare case of most likely radiation-induced glioma (RIG) with epithelioid features and the presence of molecular features consistent with RIG. This occurred 70 years after craniofacial brachytherapy. Such a late development of radiation-induced glioblastoma (RIGBM) and the advanced age of presentation for an epithelioid glioblastoma are both unique in the literature. Despite not receiving the full course of adjuvant chemotherapy after surgery and radiotherapy, the patient displayed no signs of recurrence during a 5-year follow-up. RIGBM should be further studied to reveal potential unique clinical and molecular characteristics, as well as to better predict survival and treatment response.
Collapse
Affiliation(s)
- Abdulgadir Bugdadi
- Department of Neurosurgery, INSERM Laboratory of Translational Neuropsychiatry, IMRB, Université Paris Est Créteil, Henri-Mondor University Hospital, Assistance Publique des Hôpitaux de Paris, Creteil, France
- Department of Surgery, Faculty of Medicine, Umm Al Qura University, Makkah, Saudi Arabia
| | - Mohamed Aziz Cherif
- Department of Radiotherapy, Henri-Mondor University Hospital, Creteil, France
| | | | - Pierre Brugières
- Department of Neuroradiology, Henri-Mondor University Hospital, Creteil, France
| | - Amel Marniche
- Department of Neurosurgery, INSERM Laboratory of Translational Neuropsychiatry, IMRB, Université Paris Est Créteil, Henri-Mondor University Hospital, Assistance Publique des Hôpitaux de Paris, Creteil, France
| | - Emmanuel Itti
- Department of Nuclear Medicine, Henri-Mondor University Hospital, Creteil, France
| | - Yazid Belkacemi
- Department of Radiotherapy, Henri-Mondor University Hospital, Creteil, France
| | | | - Stephane Palfi
- Department of Neurosurgery, INSERM Laboratory of Translational Neuropsychiatry, IMRB, Université Paris Est Créteil, Henri-Mondor University Hospital, Assistance Publique des Hôpitaux de Paris, Creteil, France
| | - Suhan Senova
- Department of Neurosurgery, INSERM Laboratory of Translational Neuropsychiatry, IMRB, Université Paris Est Créteil, Henri-Mondor University Hospital, Assistance Publique des Hôpitaux de Paris, Creteil, France.
| |
Collapse
|
3
|
Migliorati K, Spatola G, Giudice L, de Graaf N, Bassetti C, Giorgi C, Fontanella M, Vivaldi O, Bignardi M, Franzin A. Post Surgical Management of WHO Grade II Meningiomas: Our Experience, the Role of Gamma Knife and a Literature Review. LIFE (BASEL, SWITZERLAND) 2022; 13:life13010037. [PMID: 36675987 PMCID: PMC9865644 DOI: 10.3390/life13010037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 11/25/2022] [Accepted: 12/14/2022] [Indexed: 12/28/2022]
Abstract
Purpose: Grade II meningiomas are rarer than Grade I, and when operated on, bear a higher risk of local recurrence, with a 5-year progression free survival (PFS) ranging from 59 to 90%. Radiotherapy (RT) or radiosurgery, such as Gamma Knife radiosurgery (GKRS) can reduce the risk of relapse in patients with residual disease, even if their role, particularly after gross total resection (GTR), is still under debate. Main goal of this study was to compare the outcomes of different post-surgical management of grade II meningiomas, grouped by degree of surgical removal (Simpson Grade); next in order we wanted to define the role of GKRS for the treatment of residual disease or relapse. Methods: from November 2016 to November 2020 all patients harboring grade II meningiomas, were divided into three groups, based on post-surgical management: (1) wait and see, (2) conventional adjuvant radiotherapy and (3) stereotactic GKRS radiosurgery. Relapse rate and PFS were registered at the time of last follow up and results were classified as stable, recurrence next to or distant from the surgical cavity. In the second part of the study we collected data of all patients who underwent GKRS in our Centers from November 2017 to November 2020. Results: A total of 37 patients were recruited, including seven patients with multiple meningiomas. Out of 47 meningiomas, 33 (70.2%) were followed with a wait and see strategy, six (12.7%) were treated with adjuvant radiotherapy, and 8 patients (17.0%) with adjuvant GKRS. Follow up data were available for 43 (91.4%) meningiomas. Within the wait and see group, recurrence rates differed based on Simpson grades, lower recurrence rates being observed in three Simpson I cases (30%) compared to twelve relapses (60%) in patients with Simpson grade II/III. Finally, out of the 24 meningiomas undergoing GKRS (8 residual and 16 recurrence), 21 remained stable at follow up. Conclusions: Gross total resection (GTR) Simpson II and III have a significantly worse outcome as compared to Simpson I. The absence of adjuvant treatment leads to significant worsening of the disease progression curve. Adjuvant radiotherapy, especially GKRS, provides good local control of the disease and should be considered as an adjuvant treatment in all cases where Simpson I resection is not possible.
Collapse
Affiliation(s)
- Karol Migliorati
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Giorgio Spatola
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Lodoviga Giudice
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Nine de Graaf
- Department of General Surgery, Fondazione Poliambulanza, 25124 Brescia, Italy
- Cancer Center Amsterdam, Department of Surgery, University of Amsterdam, 1012 WX Amsterdam, The Netherlands
| | - Chiara Bassetti
- Medical Physics Unit, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Cesare Giorgi
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Marco Fontanella
- Division of Neurosurgery, Department of Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25124 Brescia, Italy
| | - Oscar Vivaldi
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Mario Bignardi
- Department of Radiation Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - Alberto Franzin
- Department of Neurosurgery, Fondazione Poliambulanza, 25124 Brescia, Italy
- Correspondence:
| |
Collapse
|
4
|
Lemmon G, Wesolowski S, Henrie A, Tristani-Firouzi M, Yandell M. A Poisson binomial-based statistical testing framework for comorbidity discovery across electronic health record datasets. NATURE COMPUTATIONAL SCIENCE 2021; 1:694-702. [PMID: 35252879 PMCID: PMC8896515 DOI: 10.1038/s43588-021-00141-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 09/16/2021] [Indexed: 01/28/2023]
Abstract
Discovering the concomitant occurrence of distinct medical conditions in a patient, also known as comorbidities, is a prerequisite for creating patient outcome prediction tools. Current comorbidity discovery applications are designed for small datasets and use stratification to control for confounding variables such as age, sex or ancestry. Stratification lowers false positive rates, but reduces power, as the size of the study cohort is decreased. Here we describe a Poisson binomial-based approach to comorbidity discovery (PBC) designed for big-data applications that circumvents the need for stratification. PBC adjusts for confounding demographic variables on a per-patient basis and models temporal relationships. We benchmark PBC using two datasets to compute comorbidity statistics on 4,623,841 pairs of potentially comorbid medical terms. The results of this computation are provided as a searchable web resource. Compared with current methods, the PBC approach reduces false positive associations while retaining statistical power to discover true comorbidities.
Collapse
Affiliation(s)
- Gordon Lemmon
- Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
- Utah Center for Genetic Discovery and Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
| | - Sergiusz Wesolowski
- Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
- Utah Center for Genetic Discovery and Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
| | - Alex Henrie
- Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
- Utah Center for Genetic Discovery and Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
| | - Martin Tristani-Firouzi
- Division of Pediatric Cardiology, University of Utah School of Medicine, Salt Lake City, UT, USA
- Nora Eccles Harrison CVRTI, University of Utah School of Medicine, Salt Lake City, UT, USA
| | - Mark Yandell
- Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
- Utah Center for Genetic Discovery and Department of Human Genetics, University of Utah, Salt Lake City, UT, USA
| |
Collapse
|
5
|
Cancer risk after breast proton therapy considering physiological and radiobiological uncertainties. Phys Med 2020; 76:1-6. [PMID: 32563956 DOI: 10.1016/j.ejmp.2020.06.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 06/04/2020] [Accepted: 06/06/2020] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND The reduced normal tissue dose burden from protons can reduce the risk of second cancer for breast cancer patients. Breathing motion and the impact of variable relative biological effectiveness (RBE) are however concerns for proton dose distributions. This study aimed to quantify the impact of these factors on risk predictions from proton and photon therapy. MATERIALS AND METHODS Twelve patients were planned in free breathing with protons and photons to deliver 50 Gy (RBE) in 25 fractions (assuming RBE = 1.1 for protons) to the left breast. Second cancer risk was evaluated with several models for the lungs, contralateral breast, heart and esophagus as organs at risk (OARs). Plans were recalculated on CT-datasets acquired in extreme phases to account for breathing motion. Proton plans were also recalculated assuming variable RBE for a range of radiobiological parameters. RESULTS The OARs received substantially lower doses from protons compared to photons. The highest risks were for the lungs (average second cancer risks of 0.31% and 0.12% from photon and proton plans, respectively). The reduced risk with protons was maintained, even when breathing and/or RBE variation were taken into account. Furthermore, while the total risks from the photon plans were seen to increase with the integral dose, no such correlation was observed for the proton plans. CONCLUSIONS Protons have an advantage over the photons with respect to the induction of cancer. Uncertainties in physiological movements and radiobiological parameters affected the absolute risk estimates, but not the general trend of lower risk associated with proton therapy.
Collapse
|
6
|
Kourinou KM, Mazonakis M, Lyraraki E, Papadaki HΑ, Damilakis J. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease. Phys Med 2019; 57:100-106. [PMID: 30738513 DOI: 10.1016/j.ejmp.2018.12.036] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 12/22/2018] [Accepted: 12/28/2018] [Indexed: 10/27/2022] Open
Abstract
PURPOSE To estimate the second cancer risk associated with Hodgkin Lymphoma (HL) radiotherapy at supradiaphragmatic or infradiaphragmatic region, using the involved field (IFRT) and the involved site radiotherapy (ISRT). MATERIALS AND METHODS IFRT and ISRT treatment plans were created for twenty HL patients. Three dimensional plans (3DRT) were employed for all patients. The organ equivalent dose (OED) and lifetime attributable risk (LAR) for organs at risk were estimated with mechanistic, plateau and bell-shaped model. Estimated risk values were compared with nominal risk of unexposed population. RESULTS For supradiaphragmatic radiotherapy, the mean OED range was 0.63-8.53 Gy and 0.63-7.26 Gy for IFRT and ISRT, respectively. The corresponding range for infradiaphragmatic radiotherapy was 0.18-7.64 Gy and 0.80-4.95 Gy. The LAR for cancer induction in the partially in field organs at risk after IFRT was 0.5%-8.0% and 0.2%-9.3% at supradiaphragmatic and infradiaphragmatic regions, respectively. The corresponding risk after ISRT method was 0.5%-5.2% and 0.9%-6.0%. Estimated cancer risk for breast, lung, thyroid, colon and rectal with ISRT was found significantly reduced compared to IFRT. The risk of secondary malignancies for lung, mouth, pharynx, rectum and colon was assessed more than 1.2 times higher than nominal risk for IFRT. The respective risk using ISRT was above nominal only for pharyngeal cancer. CONCLUSION ISRT compared with IFRT, results in decreased second cancer risk in most organs considered. Second cancer probability with IFRT was higher than the nominal risk for certain organs, while for ISRT remains higher only for pharyngeal cancer.
Collapse
Affiliation(s)
- Kalliopi M Kourinou
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion 71003, Crete, Greece.
| | - Michalis Mazonakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion 71003, Crete, Greece
| | - Efrosini Lyraraki
- Department of Radiotherapy and Oncology, Heraklion University Hospital, Heraklion 71110, Crete, Greece
| | - Helen Α Papadaki
- Department of Hematology, Heraklion University Hospital, Heraklion 71110, Crete, Greece
| | - John Damilakis
- Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion 71003, Crete, Greece
| |
Collapse
|
7
|
Hu W, Pei H, Sun F, Li P, Nie J, Li B, Hei TK, Zhou G. Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib. JOURNAL OF RADIATION RESEARCH 2018; 59:583-587. [PMID: 30124886 PMCID: PMC6151633 DOI: 10.1093/jrr/rry050] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 04/05/2018] [Indexed: 05/05/2023]
Abstract
Lung cancer is one of the highest health risks caused by ionizing radiation, which induces both direct effects and non-targeted effects. However, whether radiation-induced non-targeted effects result in epithelial-mesenchymal transition, a critical process during tumorigenesis, in non-targeted lung tissues remains unknown. In the present study, Kunming mice were subjected to whole-body, cranial or local abdominal irradiation of single-dose or fractionated 4 Gy X-rays, and the expressions of epithelial-mesenchymal transition markers in non-targeted lung tissues were assessed by both qRT-PCR and immunofluorescent staining. It was found that the epithelial marker was downregulated while the mesenchymal markers were upregulated significantly in non-targeted lung tissues of the irradiated mice. Local abdominal irradiation was more efficient in inducing epithelial-mesenchymal transition than whole-body or cranial irradiation when the fractionated irradiation method was adopted. In addition, the intraperitoneal administration of celecoxib suppressed epithelial-mesenchymal transition in the non-targeted lung tissues. In conclusion, our findings suggest that epithelial-mesenchymal transition is induced in non-targeted lung tissues, but can be suppressed by inhibition of cyclooxygenase-2 by celecoxib.
Collapse
Affiliation(s)
- Wentao Hu
- School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, P. R. China
- Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou, P. R. China
| | - Hailong Pei
- School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, P. R. China
- Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou, P. R. China
| | - Fang Sun
- Gansu Key Laboratory of Space Radiobiology, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, P. R. China
| | - Pengfei Li
- Gansu Key Laboratory of Space Radiobiology, Institute of Modern Physics, Chinese Academy of Sciences, Lanzhou, P. R. China
| | - Jing Nie
- School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, P. R. China
- Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou, P. R. China
| | - Bingyan Li
- Medical College of Soochow University, Suzhou, P. R. China
| | - Tom K Hei
- Center for Radiological Research, College of Physician and Surgeons, Columbia University, New York, NY, USA
| | - Guangming Zhou
- School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou, P. R. China
- Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Suzhou, P. R. China
| |
Collapse
|
8
|
Yonai S, Matsufuji N, Akahane K. Monte Carlo study of out-of-field exposure in carbon-ion radiotherapy with a passive beam: Organ doses in prostate cancer treatment. Phys Med 2018; 51:48-55. [DOI: 10.1016/j.ejmp.2018.04.391] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Revised: 04/09/2018] [Accepted: 04/16/2018] [Indexed: 10/17/2022] Open
|